As a publicly listed company, Nissui Pharmaceutical complies with the Financial Instruments and Exchange Act, the timely disclosure rules of securities exchanges, and other related laws, regulations, and rules. This means that we not only make timely and appropriate disclosures of information for investors but also, as a member of society, engage in fair disclosures of information to suppliers, customers, users, employees, and other stakeholders. In building an information disclosure system that excels in both transparency and reliability, our aim is to enhance shareholder value.
Nissui Pharmaceutical believes that proactive, constructive dialogue with investors is indispensable for achieving ongoing growth and increasing corporate value over the medium-to-long term. Therefore, we have created an IR system led by the director in charge of IR and strive to create opportunities for deepening understanding of our business strategies. More specifically, we hold semiannual results briefings at which the representative director explains the Company’s current status and business strategy directly to investors. In addition, we respond positively to requests for individual interviews and actively participate in conferences sponsored by investment securities firms.
Regarding dialogue with investors, we have appointed a director to oversee IR and assigned the Corporate Planning Department to handle IR activities. We have our representative director lead semiannual results briefings for investors and, in an effort to promote constructive dialogue, take steps such as making reference materials available online for investors unable to attend these briefings. Furthermore, we have created a system for making timely, fair disclosures of quarterly results and important information specified in the timely disclosure rules of securities exchanges. We believe that listening to investors, examining our management from the perspective of investors, and reflecting investor opinions in our management activities will further understanding of our management direction and contribute to ongoing growth and increases in our corporate value over the medium-to-long term.
Disclosures of information covered by disclosure rules are made via the Timely Disclosure Network (TDnet).
Nissui Pharmaceutical provides business strategy, results, key performance indicator, and other types of information crucial for making investment decisions, so that our corporate value can be properly assessed. At results briefings and on other occasions, we actively disclose not only quarterly results but also information on our medium-to-long term strategies. To fairly and rapidly disseminate information to as many investors as possible, we proactively disclose information through our website as well.
In addition, Nissui Pharmaceutical strives to reflect stock market evaluations in its management as part of its efforts to enhance management quality and transparency.
Nissui Pharmaceutical understands clearly that its own information and information of customers and others are extremely important assets and has included the proper use and management of information in its corporate ethics charter. We have established provisions on the management of internal information and the prevention of insider trading. We also strictly manage information that is particularly important and the individuals who handle it, and include information management in employee training.
To ensure fairness and prevent leaks of information on business results, the period immediately preceding a results announcement is designated as a “quiet period.” Nissui Pharmaceutical’s provisions regarding the quiet period forbid publicly commenting on, and responding to inquiries regarding business performance information. These provisions, however, do not necessarily apply to inquiries concerning previously disclosed information. Neither do they apply to information on important matters that come to light during the quiet period and are subject to timely disclosure or statutory disclosure rules.